Aytu BioPharma, Inc.
Aytu BioPharma, Inc. (AYTU) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
aytu · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.29
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.26 | ↓ 1.15% |
1-day model range: $2.25–$2.27. Peak: $2.27 (-1.15%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -24.6% |
| 2028 | $2 | -33.9% |
| 2029 | $1 | -38.0% |
| 2030 | $1 | -39.9% |
| 2031 | — | -40.8% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AYTU · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-12-10 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-09-25 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-09-25 | Maxim Group | Maintains | Buy→Buy |
| 2023-05-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-07-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-05-17 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2022-04-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-03-30 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2020-11-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-11-25 | Northland Securities | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Aytu BioPharma, Inc. (AYTU) stock. Of the recent 12 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover AYTU.
Analyst Recommendation Trends
AYTU analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$81M
↑ 51.3% YoY
Revenue Next Year
$69M
↓ 15.0% YoY
EPS This Year
$-2.49
EPS Next Year
$0.34
↓ 113.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast AYTU EPS of $-2.49 for the current fiscal year, based on estimates from 1 analysts. The AYTU revenue forecast is $81M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AYTU stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AYTU price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The AYTU short-term stock prediction for tomorrow is $2.26 (-1.15%). The AYTU stock price prediction for 2027 estimates an average of $2. The AYTU stock prediction for 2030 projects a range of $1–$1.
Aytu BioPharma, Inc. trades on NASDAQ under the ticker AYTU. The AYTU stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
AYTU forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month AYTU price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.29.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.